Array BioPharma Inc. (Nasdaq: ARRY) reported positive updated results from a Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, binimetinib and cetuximab sending the stock price up $2.42 to close at $15.56.
Array BioPharma reports updated results
January 22, 2018 at 16:21 PM EST